Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Stephan Francke"'
Publikováno v:
BMC Genomics, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Background Atabecestat, a potent brain penetrable BACE1 inhibitor that reduces CSF amyloid beta (Aβ), was developed as an oral treatment for Alzheimer’s disease (AD). Elevated liver enzyme adverse events were reported in three studies alt
Externí odkaz:
https://doaj.org/article/70c276bd11684fa7883185e75cf3c055
Autor:
Joseph Massarella, Byron DeLemos, Stephan Francke, Sergio Fonseca, Jay Ariyawansa, Thomas Murtaugh, Subusola Vaughan, Jaya Natarajan
Publikováno v:
Clinical Pharmacology in Drug Development
We evaluated the effects of therapeutic and supratherapeutic doses of tramadol hydrochloride on the corrected QT (QTc) interval in healthy adults (aged 18‐55 years) in a randomized, phase I, double‐blind, placebo‐ and positive‐controlled, mul
Autor:
Bhavna Solanki, Ellen Scheers, Andrew Jadwin, Rao N.V.S. Mamidi, Reyna Favis, Damayanthi Devineni, Stephan Francke
Publikováno v:
The Journal of Clinical Pharmacology. 55:1061-1072
O-glucuronidation is the major metabolic elimination pathway for canagliflozin. The objective was to identify enzymes and tissues involved in the formation of 2 major glucuronidated metabolites (M7 and M5) of canagliflozin and subsequently to assess
Autor:
Chih Cherng Lu, Joris Vandenbossche, Stephan Francke, Henry M Richards, An Van den Bergh, Monique A. Franc
Publikováno v:
The Journal of Clinical Pharmacology. 54:1170-1179
This open-label, single-center, phase I study (NCT1487564) investigated the effect of uridine diphosphate-glucuronosyltransferase2B7 (UGT2B7 * 2) genetic polymorphism (H268Y) on the pharmacokinetics (PK) and safety of a single, oral, 16-mg dose of OR
Autor:
Lei Li, Peter M.A. Groenen, Larry M. Tremaine, Stephan Francke, Keith Johnson, Kimberly Pearson, Terrye Aigeldinger Delmonte, William Brian, Jean-Claude Marshall
Publikováno v:
Pharmacogenomics. 16(18)
Genetic polymorphisms in metabolizing enzymes and drug transporters have been shown to significantly impact the exposure of drugs having a high dependence on a single mechanism for their absorption, distribution or clearance, such that genotyping can
Autor:
Richard S. Strauss, Qingqin S. Li, Maria C. Athanasiou, Stephan Francke, James M. Lenhard, Yiping Zhan, Karel Konvicka
Publikováno v:
Pharmacogenetics and genomics. 26(2)
OBJECTIVE Clinical response to topiramate can vary greatly in obese patients. Identifying genetic variants associated with treatment response could help gain insight into the mechanism of action of topiramate. Little is known about the relationship b
Autor:
Juan Jose Perez-Ruixo, Monique A. Franc, Stephan Francke, Vladimir Piotrovsky, Peter Zannikos, Vural Ozdemir
Publikováno v:
Cancer Chemotherapy and Pharmacology. 58:681-691
Objective: Evaluate the effect of CYP2D6 genotype on the pharmacokinetics of tipifarnib. Methods: A total of 268 subjects included in six clinical trials were treated orally with tablet formulation of tipifarnib, as a single dose or as multiple b.i.d
Autor:
Philippe Passa, Teman K. Gunness, Annick Hebe, Saida Lahmidi, Laetitia Corset, Uday S. Ramjuttun, Sarojini Jankee, Solange Lee Kwai Yan, Christian Dina, Philippe Froguel, Frédéric Leprêtre, Cécile Lecoeur, Vinod Balgobin, Corinne Lacquemant, Meera Manraj, Stephan Francke
Publikováno v:
Scopus-Elsevier
Prevalence of coronary heart disease (CHD), of type 2 diabetes (T2DM) and of the metabolic syndrome are in Mauritius amongst the highest in the world. As T2DM and CHD are closely associated and have both a polygenic basis, we conducted a 10 cM genome
Autor:
Mouna Houari, Nathalie Lorentz, Vincent Vatin, Philippe Froguel, Christian Dina, Emmanuel Vaillant, Karine Clément, Séverine Dubois, Bernard Guy-Grand, Stephan Francke, Arnaud Basdevant, Jörg Hager
Publikováno v:
Nature Genetics. 20:304-308
Obesity, a common multifactorial disorder, is a major risk factor for type 2 diabetes, hypertension and coronary heart disease1 (CHD). According to the definition of the World Health Organization (WHO), approximately 6-10% of the population in Wester
Autor:
Christian Dina, P. Behn, Arnaud Basdevant, M. A. Permutt, Bernard Guy-Grand, Karine Clément, Philippe Froguel, J. Hager, Stephan Francke, Vincent Vatin, H. Inoue
Publikováno v:
Human Genetics. 100:491-496
Family studies have shown that in some populations up to 75% of the variation of body mass index can be explained by genetic factors. However, in humans, no major obesity gene has been identified to date. In contrast, there are a number of geneticall